[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP2608827B1 - Verfahren und system zur bestimmung von informationen im zusammenhang mit einem arzneimittelreservoir - Google Patents

Verfahren und system zur bestimmung von informationen im zusammenhang mit einem arzneimittelreservoir Download PDF

Info

Publication number
EP2608827B1
EP2608827B1 EP11752511.3A EP11752511A EP2608827B1 EP 2608827 B1 EP2608827 B1 EP 2608827B1 EP 11752511 A EP11752511 A EP 11752511A EP 2608827 B1 EP2608827 B1 EP 2608827B1
Authority
EP
European Patent Office
Prior art keywords
drug reservoir
drug
delivery device
circuit
reservoir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP11752511.3A
Other languages
English (en)
French (fr)
Other versions
EP2608827A2 (de
Inventor
Shane Alistair Day
Barry Yates
Richard James Vincent Avery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Priority to EP11752511.3A priority Critical patent/EP2608827B1/de
Publication of EP2608827A2 publication Critical patent/EP2608827A2/de
Application granted granted Critical
Publication of EP2608827B1 publication Critical patent/EP2608827B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/50—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
    • A61M5/5086—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile for indicating if defective, used, tampered with or unsterile
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/13—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/60—General characteristics of the apparatus with identification means

Definitions

  • Specific embodiments of the present disclosure relate to a method and system for determining information related to a drug reservoir, particularly a drug reservoir containing a medicament.
  • medicament reservoirs may comprise an ampoule, a cartridge, or a vial and may be used with a medical delivery device.
  • exemplary medical delivery devices could comprise a syringe, a pen type syringe, a pump, or other similar device that requires a reservoir containing at least one medicament.
  • the present disclosure is generally directed to reservoirs, particularly reservoirs containing a medicament. More particularly, the present disclosure is generally directed to determining information related to a drug reservoir, which may help ensure that a delivery device can only be used with a drug reservoir for which it is intended.
  • medicament reservoirs may comprise an ampoule, a cartridge, a vial, or a pouch, and may be used with a medical delivery device.
  • Exemplary medical delivery devices include, but are not limited to syringes, pen type injection syringes, credit-card-shaped injection devices, pumps, inhalers, or other similar injection or infusing devices that require at least one reservoir containing at least one medicament.
  • Medicament reservoirs such as ampoules, cartridges, or vials are generally known. Such reservoirs are especially used for medicaments that may be self administered by a patient. For example, with respect to insulin, a patient suffering from diabetes may require a certain amount of insulin to either be injected via a pen type injection syringe or infused via a pump. With respect to certain known reusable pen type drug delivery devices, a patient may load a cartridge containing the insulin into a proximal end of a cartridge holder. After the cartridge has been correctly loaded, the user may then be called upon to select a dose of medicament. Multiple doses may be dosed from the cartridge.
  • the drug delivery device comprises a reusable device
  • the cartridge holder may be disconnected from the drug delivery device and the empty cartridge may be removed and replaced with a new cartridge.
  • Most suppliers of such cartridges recommend that the user may dispose of the empty cartridges properly.
  • the drug delivery device comprises a disposable device, once the cartridge is empty, the user may be recommended to dispose of the entire device.
  • Such known self administration systems requiring the removal and reloading of empty cartridges have certain limitations.
  • a user may simply load a new cartridge into the delivery system without the drug delivery device or without the cartridge having any mechanism of preventing cross use of an incorrect cartridge. That is, the drug delivery device does not have a mechanism for determining whether the medicament contained in the cartridge is indeed the correct type of medicament to be administered by the patient.
  • certain known drug delivery devices do not present a mechanism for determining whether the correct type of medicament within the cartridge should be used with that particular drug delivery system. This potential problem could be exacerbated given that certain elderly patients, such as those suffering from diabetes, may have limited manual dexterity. Identifying an incorrect medicament is quite important, since the administration of a potentially incorrect dose of a medicament such as a short-acting insulin in lieu of a long-insulin could result in injury or even death.
  • Some drug delivery devices or systems may use a color coding scheme to assist a user or care giver in selecting the correct cartridge to be used with a drug delivery device.
  • color coding schemes pose challenges to certain users, especially those users suffering from poor eyesight or color blindness: a situation that can be quite prevalent in patients suffering from diabetes.
  • Document US 2003/0055685 A1 discloses systems and methods for monitoring administration of a medical product within a delivery device using a medicine data storage device attached to the delivery device.
  • Document WO 2009/015933 A1 relates to a medicament reservoir adapted to contain a medicament and comprising an identification code with a plurality of electrode arrays arranged on an exterior surface part of the reservoir.
  • Document US 2003/0006209 A1 discloses a container for a substance having an associated identifying element.
  • Document WO 2007/041843 A1 discloses a smart medical compliance method and system to prevent adverse drug events through the use of protocols that uniquely identify the patient, care provider, medication and/or medical device that is to be used with radiofrequency identification.
  • Document WO 2010/029156 A1 discloses a cartridge for a medical device comprising an ordered arrangement of N electrical components.
  • Document EP 1 776 975 A2 relates to a medication injector apparatus.
  • Document WO 01/58236 A2 relates to improvements in and relating to controlling drug delivery apparatus and document US 2005/0107899 A1 relates to a configurable device and method for dispensing of a substance.
  • the problem to be solved by the present invention is to provide a medical delivery device where the safety of the user is increased.
  • the method comprises a detector feature determining an electrical property related to a coded material disposed on the drug reservoir.
  • the coded material comprises at least one circuit.
  • the at least one circuit may be an RCL circuit.
  • the at least one circuit may comprise at least one fused conductor.
  • the method further includes determining information related to the drug reservoir based at least on the determined electrical property.
  • the method may be used for test purposes.
  • the method may be applicable for non-therapeutic and/or non-surgical purposes.
  • the method further comprises the step of, based on the determined information, determining that the drug reservoir is not intended for use with the medical delivery device.
  • controlling dose selection based on the identified drug reservoir comprises preventing dose selection when the identified drug reservoir is not intended for use with the medical delivery device.
  • Controlling dose selection based on the identified drug reservoir further comprises setting a maximum dose or setting a minimum dose when the identified drug reservoir is intended for use with the medical delivery device. Additionally or alternatively, controlling dose selection based on the identified drug reservoir may comprise controlling the dosing frequency.
  • the method further comprises controlling dispensing of the drug based on the identified drug reservoir.
  • Controlling dispensing of the drug based on the identified drug reservoir comprises preventing dispensing of the drug when the identified drug reservoir is not intended for use with the medical delivery device.
  • Controlling dispensing of the drug based on the identified drug reservoir further comprises controlling a dispense speed and a required dispense force when the identified drug reservoir is intended for use with the medical delivery device.
  • the coded material for the drug reservoir may be disposed on a location selected from the group consisting of a location on the drug reservoir, a location on a label of the drug reservoir, a location on a holder of the drug reservoir, a location on a box of the drug reservoir, a location on a security wrapping of the drug reservoir, and a location on a blister pack of the drug reservoir.
  • the at least one component of the at least one circuit may be printed onto the drug reservoir.
  • the method may further comprise the step of determining a second electrical property of the at least one circuit. Based on the second property, information, in particular further information, related to the drug reservoir may be determined.
  • the detector feature may comprise an oscillator.
  • the determined electrical property may comprise at least one of a resonant frequency of the at least one circuit and an attenuation of the at least one circuit.
  • the at least one circuit may comprise a low-pass filter.
  • the at least one circuit may comprise a high-pass filter.
  • the determined electrical property may comprise at least one of a frequency passed and a frequency blocked.
  • the at least one circuit may be a single-layer circuit. Alternatively, the at least one circuit may be a double-layer circuit.
  • the detector feature may comprise an electrical connector.
  • the detector feature may comprise a plurality of connectors.
  • the electrical connector may be a contact, in particular a metal contact.
  • the electrical connector may be a contactless electrical connector.
  • the information related to the drug reservoir may be information selected from the group consisting of drug type, drug concentration, a manufacturing date of the reservoir, an expiration date of the drug, and a storage condition of the drug.
  • the step of determining information related to the drug reservoir may be performed as a user loads the drug reservoir in a medical delivery device.
  • the method may further comprise displaying an indication that the drug reservoir is not intended for use with the medical delivery device.
  • the method may further comprise the step of identifying the drug reservoir based on the information.
  • the invention relates to a medical delivery device as defined in independent claim 1.
  • the medical delivery device comprises a drug reservoir holder.
  • the drug reservoir holder is operable to receive a drug reservoir.
  • the medical delivery device comprises a detector for detecting information related to the drug reservoir and being configured to be operable to determine an electrical property related to a coded material disposed on the drug reservoir, wherein the coded material comprises at least one circuit and, based at least on the determined electrical property, to determine information related to the drug reservoir.
  • the detector may comprise a connector.
  • the detector comprises a processor and a data storage comprising instructions executable by the processor.
  • the medical delivery device is configured to perform the previously described method.
  • the medical delivery device is capable of determining information related to the drug reservoir.
  • the data storage comprises instructions executable by the processor, wherein, when a user attempts to load the drug reservoir into the medical delivery device, the instruction are further executable by the processor to, based on the determined information, identify the drug reservoir, determine whether the drug reservoir is intended for use with the medical delivery device, control dose selection based on the identified drug reservoir, wherein controlling dose selection comprises preventing dose selection when the identified drug reservoir is not intended for use with the medical delivery device, and setting a maximum dose or setting a minimum dose when the identified drug reservoir is intended for use with the medical delivery device and to control dispensing of the drug based on the identified drug reservoir, wherein controlling dispensing of the drug based on the identified drug reservoir comprises preventing dispensing of the drug when the identified drug reservoir is not intended for use with the medical delivery device and controlling a dispense speed and a required dispense force when the identified drug reservoir is intended for use with the medical delivery device.
  • the coded material includes at least one circuit.
  • the at least one circuit may be an RCL circuit.
  • the detector is operable to determine information related to the drug reservoir based at least on the determined electrical property.
  • the instructions may also be executable by the processor to determine information related to the drug reservoir based at least on the determined electrical property.
  • the medical delivery device comprises a display.
  • the display may be configured to display at least a portion of the information related to the drug reservoir.
  • At least one component of the at least one circuit is printed onto the drug reservoir.
  • the detector feature comprises an oscillator.
  • the determined electrical property may comprise at least one of a resonant frequency of the at least one circuit and an attenuation of the at least one circuit.
  • the at least one circuit comprises a low-pass filter.
  • the at least one circuit may comprise a high-pass filter.
  • the determined electrical property may comprise at least one of a frequency passed or blocked.
  • the detector feature comprises an electrical connector.
  • the electrical connector may be a contact, in particular a metal contact.
  • the electrical connector may be a contactless electrical connector.
  • the drug reservoir is selected from the group consisting of a drug cartridge and a drug pouch.
  • the instructions are further executable by the processor to display an indication that the drug reservoir is not intended for use with the medical delivery device.
  • the instructions are further executable by the processor to prevent insertion of the drug reservoir into the medical delivery device.
  • the instructions are further executable by the processor to identify the drug reservoir based on the determined information related to the drug reservoir.
  • the disclosed method and system may allow for identifying information related to a drug reservoir by an electronic means.
  • the proposed system and method may help a user to distinguish between medicament reservoirs, thereby ensuring that a medical delivery device can only be used with a medicament reservoir for which it is intended.
  • a given medical delivery device or drug delivery device may be intended to only be used with a single drug reservoir.
  • the disclosed system and method may help a user to ensure that only the single given drug reservoir is used with the given drug delivery device.
  • a given drug delivery device may be intended for use with multiple drug reservoirs.
  • the disclosed system and method may help a user to ensure that only the intended reservoirs are used with the drug delivery device.
  • the disclosed system and method may also inform a user (or, more generally, any individual dealing with drug reservoirs in any capacity, such as manufacture, shipping, storage, etc.) of other useful information regarding the drug reservoir, such as required storage conditions for the reservoir and/or expiration date of the reservoir.
  • information regarding the drug reservoir may be determined by determining an electrical property related to a coded material by using a detector feature. A method and system for identifying information related to the drug reservoir are described in greater detail below in the following subsections.
  • Figure 1 depicts a system or detector feature 100 for determining information related to a coded material.
  • This system 100 may determine information related to a drug reservoir.
  • System 100 includes a processor 102 and a connector 104.
  • the system 100 may also comprise data storage 108 comprising instructions 110 executable by the processor 102 to carry out the functions described herein.
  • the processor 102 may comprise a single processor such as a general purpose microprocessor or multiple (e.g. parallel) processors.
  • the data storage 108 may take various forms, in one or more parts, such as a non-volatile storage block and/or a removable storage medium. Data storage 108 may also include data 112, which may be used for carrying out the functions described herein.
  • system 100 may be provided on or in a drug delivery device, such as syringes, pen-type injection syringes, credit-card-shaped injection devices, pumps, inhalers, or other similar injection or infusing devices that require at least one reservoir containing at least one medicament.
  • a drug delivery device such as syringes, pen-type injection syringes, credit-card-shaped injection devices, pumps, inhalers, or other similar injection or infusing devices that require at least one reservoir containing at least one medicament.
  • system 100 may be provided in drug delivery device 300 shown in Figure 3A .
  • the drug delivery device 300 comprises a housing 302 having a first reservoir retaining part 304, and second main (exterior) housing part 306.
  • Housing part 306 may include a dose setting mechanism.
  • a first end of the reservoir retaining part or cartridge holder 304 and a second end of the main housing 306 are secured together by retaining features 308.
  • the reservoir retaining part 304 is secured within the second end of the main housing 306.
  • the pen type syringe may comprise a re-usable or a disposable pen type syringe. Where the syringe comprises a re-usable device, the cartridge holder 304 and the dose setting mechanism are removably coupled together. In a disposable device 300, they are permanently coupled together.
  • a drug reservoir such as drug reservoir 320 shown in Figure 3B from which a number of doses of a medicinal product 322 may be dispensed, may be inserted in the reservoir retaining part 304.
  • the drug reservoir 320 contains a type of medicament or medicinal product 322 that must be administered often, such as once or more times a day.
  • One such medicament 322 is insulin.
  • the term "medicament”, as used herein, preferably means a pharmaceutical formulation containing at least one pharmaceutically active compound, wherein in one embodiment the pharmaceutically active compound has a molecular weight up to 1500 Da and/or is a peptide, a proteine, a polysaccharide, a vaccine, a DNA, a RNA, an enzyme, an antibody, a hormone or an oligonucleotide, or a mixture of the above-mentioned pharmaceutically active compound, wherein in a further embodiment the pharmaceutically active compound is useful for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis, wherein in a further embodiment the pharmaceutically active compound comprises
  • Insulin analogues are for example Gly(A21), Arg(B31), Arg(B32) human insulin; Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
  • Insulin derivates are for example B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl- ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-Y-glutamyl)-des(B30) human insulin; B29-N-(N-lithocholyl-Y-glutamyl)-des(B30) human insulin; B29-N-( ⁇ -carboxyheptadecanoyl)-des(B30) human insulin and B29-N-( ⁇ -carbox
  • Exendin-4 for example means Exendin-4(1-39), a peptide of the sequence H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2.
  • Exendin-4 derivatives are for example selected from the following list of compounds:
  • Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008, Chapter 50 , such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, Goserelin.
  • Gonadotropine Follitropin, Lutropin, Choriongonadotropin, Menotropin
  • Somatropine Somatropin
  • Desmopressin Terlipressin
  • Gonadorelin Triptorelin
  • Leuprorelin Buserelin
  • Nafarelin Goserelin.
  • a polysaccharide is for example a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof.
  • An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.
  • Pharmaceutically acceptable salts are for example acid addition salts and basic salts.
  • Acid addition salts are e.g. HCI or HBr salts.
  • Basic salts are e.g. salts having a cation selected from alkali or alkaline, e.g. Na+, or K+, or Ca2+, or an ammonium ion N+(R1)(R2)(R3)(R4), wherein R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1-C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group.
  • solvates are for example hydrates.
  • the system 100 is provided at or near the interface between the reservoir retaining part 304 and the main housing part 306.
  • the system 100 may detect information related to the reservoir 322 being inserted.
  • system 100 may be provided at other locations on or in drug delivery device 300.
  • system 100 may be provided within reservoir retaining part 304 near the distal end of the drug delivery device 300.
  • system 100 may operate to identify information related to drug reservoir 320.
  • system 100 may operate to identify information related to the drug reservoir 320 by first identifying a coded material, such as coded material 120 (see Figure 1 ) disposed on drug reservoir 320.
  • Coded material 120 includes at least one circuit element 122 having a predefined electrical property or properties that can be detected by system 100.
  • the coded material 120 can be applied to a reservoir such as a cartridge, vial, ampoule, pouch, or container. This coded material 120 may serve to indicate information about the drug reservoir the coded material is disposed on.
  • the coded material 120 is disposed directly on a drug reservoir, such as drug reservoir 320 depicted in Figure 3B .
  • coded material 120 is disposed near the proximal end of drug reservoir 320. However, in other embodiments the coded material 120 may be disposed elsewhere, perhaps near the distal end of drug reservoir 320.
  • the circuit 122 may be printed on or otherwise formed on the coded material 120. The coded material 120 may then be attached to the drug reservoir 320. However, in other examples, the circuit 122 itself may be the coded material. For instance, the circuit 122 may be printed or otherwise formed on a label for the drug reservoir 320 prior to the label being attached to the reservoir 320.
  • FIG. 2 is a flowchart of an exemplary method that may be carried out by detector feature 100, in accordance with an exemplary embodiment.
  • method 200 begins at step 202, where system or detector feature 100 determines an electrical property related to the circuit 122 of coded material 120. Then, at step 204, based on the determined electrical property, detector feature 100 determines information related to the drug reservoir 320. These steps are further explained in the following subsections.
  • Step 202 may occur at various stages.
  • the detector feature 100 may determine an electrical property of the coded material 120 before, during, or after the drug reservoir 320 is inserted into a drug delivery device 300.
  • the connector 104 may communicate with the circuit 122 of the coded material 120, so system 100 may determine an electrical property of the coded material 120.
  • the connector 104 may be electrically connected to or otherwise coupled with circuit 122.
  • the connector 104 may comprise a plurality of different connectors, such as connectors 104a-c, that each serve to provide a different connection to the coded material 120.
  • the coded material 120 is preferably disposed on a drug reservoir, such as drug reservoir 320 depicted in Figure 3B .
  • the coded material 120 may be on the reservoir, ferrule, bung, label, connector or an adaptor.
  • the coded material 120 may be disposed elsewhere, such as on the box of a drug reservoir 320 or drug reservoirs 320.
  • the detector feature 100 may determine an electrical property or electrical properties of the circuit 122.
  • the circuit 122 may be manufactured and designed so as to have a given, predetermined electrical property or electrical properties that can be detected by system 100.
  • the circuit 122 may be any type of circuit with a predetermined electrical property that can be detected, such as any RCL circuit.
  • An example RCL circuit 400 is depicted in Figure 4 .
  • Circuit 400 includes a resistor 402, an inductor 404, and a capacitor 406.
  • the resistor 402, inductor 404, and capacitor 406 may be selected and arranged in order to yield a predetermined electrical property, such as a predetermined resistance, a predetermined capacitance, and a predetermined inductance.
  • An RCL circuit in accordance with the present disclosure may include any combination of resistors 402 (R), capacitors 404 (C), and/or inductors 406 (L) (i.e. RCL, RC, RL, CL, R, C, or L).
  • RCL resistors 402
  • C capacitors 404
  • L inductors 406
  • different circuits 122 having different electrical properties may each identify different drug reservoirs 320 or different information about a given drug reservoir 320 or reservoirs 320.
  • the various components of the circuit 322 may be printed onto the drug reservoir 320 or onto a label to be attached to the drug reservoir 320.
  • the printing may be accomplished by numerous circuit printing methods now known in the art or later developed.
  • the printing method may be a screen-printing method or an ink-jet printing method. Contacts or circuit tracks can be printed using silver-loaded ink, and resistors 402 can be printed using carbon in the ink. If the circuit 122 includes both capacitors 406 and inductors 404, the circuit 122 may need to be printed in two or more layers. Multiple circuit layers may be achieved by covering the first layer of print with a printed insulator, with holes in the printed-insulator layer to allow for connections between circuit layers. A second conductive layer may then be printed on top of the printed-insulator layer.
  • connector 104 may be any electrical connector.
  • connector 104 may be a sprung metal contact.
  • the connector 104 may include a plurality of sprung metal contacts.
  • the connector 104 may be a contactless connector.
  • the connector 104 may act as a contactless connector through magnetic induction, capacitive coupling, or radio frequency (RF).
  • RF radio frequency
  • system or detector feature 700 includes a connector 702 that is in communication with an oscillator circuit 704.
  • the oscillator circuit 704 is controlled by a controller 706.
  • This system 700 may determine electrical properties of a coded material 708 without physically connecting to the coded material 708.
  • a contactless connector 702 may increase robustness and/or reduce the need to align the coded material 708 with the system 700.
  • the detector feature 700 may operate to determine an electrical property of the circuit of the coded material 708 even without being aligned to be adjacent to the circuit, as may be required in the case of a sprung metal contact.
  • Coding of information by way of drug reservoirs may be achieved in numerous ways.
  • coding may be achieved by measurement of the resistance, capacitance, and/or inductance between each connector. Measurement of the resistance, capacitance, and/or inductance between each connector may be achieved by, for example, utilizing an analog-to-digital converter connected to a microcontroller or other processor.
  • Figure 5 depicts a detector feature 500 including an analog-to-digital converter connected to a microcontroller that may be used to determine an electrical property or properties of coded material 502.
  • the system may include an oscillator allowing measurement of the resonant frequency or attenuation of a given circuit.
  • Figure 6 depicts a detector feature 600 that includes an oscillator formed by a capacitor 610 and a resistor 608, with an inverter 602 and a microcontroller 604.
  • the detector feature 600 may determine information about a coded material 606.
  • the resistor 608 and the capacitor 610 on the 606 coded material of a given drug reservoir tune the oscillator circuit of the detector feature 600.
  • the determined information about the coded material 606 may then be decoded with the low-cost microcontroller 604 in order to determine an electrical property or properties of the coded material 606.
  • the circuit may include a low-pass filter(s) or a high-pass filter(s), allowing measurements of the frequencies passed or blocked.
  • Resistors and capacitors in the coding material can be arranged to form a low pass filter shown in Figure 13A , or a high pass filter shown in Figure 13B .
  • Connectors can be arranged so that an input voltage Vin can be applied, and an output voltage Vout can be measured.
  • the system 100 may then determine information related to the drug reservoir 320.
  • the electrical property or properties of the circuit 122 or circuits of the coded material 120 may vary for different types of drug reservoirs, and various electrical properties may be associated with various information related to drug reservoirs.
  • a first given coded material having a first given electrical property e.g. a first resistance
  • a second given coded material having a second given electrical property e.g. a second resistance
  • a third coded material having a third given electrical property e.g. a given capacitance
  • system 100 may comprise data storage 108 that includes data 112.
  • This data 112 may comprise a database of information that links a plurality of electrical properties to respective information regarding a given drug reservoir.
  • the database may include information that links a given electrical property to a type of drug the drug reservoir contains.
  • the electrical property of the coded material may serve to identify other information about a drug reservoir.
  • the information related to the drug reservoir may be information related to drug type, a drug concentration, a manufacturing date of the reservoir, an expiration date of the drug, and a storage condition of the drug (e.g. required storage temperature). Other types of information about a drug reservoir are possible as well.
  • a large amount of information may be coded (e.g. distinguishing a large number of medicament reservoirs) by varying the electrical property or properties of the coded material or coding features disposed on the drug reservoir. For instance, multiple materials may be provided on a drug reservoir in order to provide coding for drug reservoirs. For example, three circuits each having a unique electrical property may be provided.
  • additional informational coding may be achieved in various ways.
  • the position of the coded material may also be used for identification purposes.
  • position of the coded material 120 relative to a standard feature may be used to identify information about the drug reservoir 320.
  • system 100 may be further configured to detect the position of the coded material 120.
  • the axial length of the coded material 120 from a proximal end of the reservoir 320 may provide information related to the drug reservoir 320.
  • the system 100 may identify coded material 120 based on the size (e.g. the axial, circumferential, and/or radial extent of the coded material) or orientation (e.g. axial strips, circumferential rings, or 2D pattern) of the coded material 120.
  • the number of circuits 122 incorporated within the coded material 120 may also convey information about the drug.
  • system 100 may react to the identified information at various stages in an operating sequence of the drug delivery device 300.
  • system 100 may be configured to take certain actions when a drug reservoir 320 is identified. For instance, the system 100 may react to the information and take an appropriate action during (i) loading of the device 300, (ii) dose selection, and/or (iii) dispensing of the drug. Other stages are possible as well. Beneficially, during these steps, the system 100 may help a user identify whether the drug reservoir 320 being loaded or that is already loaded is intended for the drug delivery device 300.
  • the step of determining information related to the drug reservoir 320 may be performed as a user loads the drug reservoir 320 in drug delivery device 300.
  • System 100 may identify an electrical property of circuit 122 of the coded material 120 and, then, may determine, based on the electrical property, whether the drug reservoir 320 is intended for use with the drug delivery device 300.
  • the system 100 may display an indication that the drug reservoir 320 is not intended for use with the drug delivery device 300.
  • the system 100 may comprise a display feature 114 that is in communication with the processor 102.
  • display feature 114 could be located on an outer edge of housing 306, as shown in Figure 3A .
  • This display feature 114 could indicate that the drug reservoir 320 is incorrect.
  • the display feature 114 may display a red dot or red "X" when an incorrect drug reservoir 320 is loaded.
  • the display feature 114 may also operate to indicate when a correct drug reservoir 320 is loaded.
  • the display feature 114 may display a green dot when a correct drug reservoir 320 is loaded.
  • Other types of indications are possible as well, such as an audible indication.
  • the system 100 may operate to prevent the insertion of the drug reservoir 320 into the drug delivery device 300.
  • preventing insertion of the drug reservoir 320 may comprise activating an electronically-controlled latch, such as latch 116 shown in Figure 1 , which prevents insertion of the drug reservoir 320.
  • System 100 may also be configured to prevent the reset of a spindle, such as spindle 312 shown in Figure 3A , of a dose setting mechanism of the drug delivery device if the user attempts to load the drug delivery device 300 with an incorrect drug reservoir or container 320.
  • system 100 may be configured to block the insertion of all drug reservoirs 320 other than a given drug reservoir 320 for which the drug delivery 300 device is intended.
  • the system 100 may be configured to only block drugs that are considered dangerous for using with the device 300 (e.g. a short-acting drug could be fitted into a device intended for long-acting insulin, or a low-concentration drug could be fitted into a device intended for a high-concentration drug, but not vice versa).
  • the method and system may also react to an identified drug reservoir 320 and take an appropriate action during a dose selection phase (i.e. when a user is selecting a dose).
  • system 100 may be configured to control dose selection based on the identified drug reservoir 320. Similar to preventing loading of an incorrect drug reservoir 320, system 100 may be configured to prevent dose selection when the identified drug reservoir 320 is not intended for use with the drug delivery device 300.
  • System 100 may, for instance, trigger a latch, such as latch 116, that prevents a user from setting a dose when an incorrect reservoir 320 is loaded in the drug delivery device 300.
  • system 100 may control dose selection based on the identified drug reservoir 320 by setting or enforcing a maximum dose.
  • the drug reservoir 320 may contain a drug that should only be dosed in small increments (e.g. 20 units or less).
  • the system 100 may be configured to prevent a user from setting a dose greater than 20 units when such a drug reservoir 320 is inserted in the drug delivery device 300.
  • system 100 may control dose selection based on the identified drug reservoir 320 by setting or enforcing a minimum dose.
  • system 100 may control dose selection based on the identified drug reservoir 320 by controlling the dosing frequency. For instance, if a drug should not be dosed more than once a day, after a user injects a dose, the system 100 may be configured to lock the drug delivery dose setting mechanism out for a 24-hour period. For example, the system 100 may activate the electronic latch 116 to prevent dose setting for the 24-hour period.
  • the method and system may also react and take an appropriate action during the dispensing phase (i.e. when a user dispenses the drug).
  • the system 100 may be configured to control dispensing of the drug based on the identified drug reservoir 320. For example, similar to preventing loading of an incorrect drug reservoir 320 and dose selection with an incorrect reservoir 320, system 100 may be configured to prevent dispensing when the identified drug reservoir 320 is not intended for use with the drug delivery device 300.
  • controlling dispensing of the drug based on the identified drug reservoir 320 may include controlling a dispense speed and/or a required dispense force.
  • Controlling a dispense speed and/or a required dispense force may be beneficial for various reasons. For example, certain drugs may require an increased dispense force due to crystallizing on the bung and/or high viscosity. In such a case, it may be beneficial to inject the drug slowly in order to reduce the force needed by a motorized drive. Further, in such a case, injecting such a drug may be painful for the user, so slower injection may reduce any pain.
  • one other reason to control speed/force is to detect abuse loads, e.g. to detect blockages it is necessary to know what force is 'normal' for a given drug at a given speed.
  • system 100 may be used to identify the time that has elapsed since drug reservoir 320 was loaded into the drug delivery device 300. For example, the time at which the cartridge holder latch was last operated could be recorded into memory in the device 300, or on the drug reservoir 320.
  • System 100 may also be used as part of a 'closed loop' drug pump.
  • the pump would detect the patient's needs, for example using a Blood Glucose Monitor, and then dispense the correct amount of drug, for example insulin.
  • the system 100 may be able to vary the volume of drug dispensed to allow for variables such as drug concentration, or drug type.
  • system 100 may be a stand-alone device, such as a scan gun or used for identifying information related to drug reservoirs 320 or a drug-identification base station.
  • the stand-alone system may be used by, for example, a patient or medical staff personnel, or a drug manufacturer in order to identify information related to drug reservoirs 320.
  • Such a stand-alone device may be used for a variety of reasons.
  • the stand-alone system may be used to aid with storage or shipping of drug reservoirs 320.
  • the system 100 may be used to identify the expiration date of the drug reservoir 320.
  • system 100 may be used to identify required storage conditions for the drug reservoir 320. It may also be possible to record storage conditions experienced by a cartridge or drug reservoir 320, e.g. with a temperature sensitive label, and for this information to be read by the device.
  • the circuit 122 or circuits of the coded material 120 may be designed and manufactured in any way currently known in the art or later developed.
  • a standard circuit may be manufactured, and the standard circuit can then be modified in various ways based on the information the modified circuit is intended to represent. This practice of manufacturing a standard circuit and, thereafter modifying it may be particularly beneficial or useful for coding small batches of drug reservoirs 320.
  • some conductors may be fused or cut to indicate a type of a drug or other information about a drug reservoir 320.
  • Figures 8A-c depict such an example.
  • Figure 8A depicts a standard circuit 800
  • Figure 8B depicts a modified circuit 802.
  • circuit 802 has fused conductors 804a-e.
  • the fused conductors 804a-e cause circuit 802 to be the equivalent of the circuit 804 shown in 8C. Fusing conductors in different ways will create circuits having different properties. It should be appreciated that many examples and equivalent circuits are possible.
  • the standard circuit 800 may comprise of building blocks of circuits, or a number of separate circuits.
  • a mechanical feature on the drug reservoir 320 would be in a different position relative to the circuits for each different drug, and the drug delivery device 300 would recognize the drug by where the circuits are connected to the device 300.
  • Two or more of the connectors might form a short-circuit, which would bypass part of the circuit 800.
  • FIG. 9A illustrates an example of a detector feature 904 having a plurality of connectors 1 to 5 connected to a coded material 900 having a circuit 902 comprising two capacitors C 12 , C 45 and two resistors R 23 , R 34 .
  • a circuit 906 there are connectors at positions 1 to 4, but not at position 5, and connectors 2 and 4 are connected together by a circuit 906 within the device 300.
  • This arrangement of connectors 1-5 in the device 300 causes the circuit 902 of the coded material shown in Figure 9A to be the equivalent of the circuit 908 shown in Figure 9B .
  • the coded material 120 having the circuit 122 may be applied around the full circumference of the drug reservoir.
  • coded material 120 is applied around the full circumference of drug reservoir 1000.
  • the orientation of the drug reservoir 1000 as it is loaded is not important.
  • the coded material 120 may be a discrete area, (e.g. a strip) of material that is not disposed around the full circumference of a reservoir, such as the strip of coded material 120 on drug reservoir 1002 shown in Figure 10B .
  • position of the coded material 120 relative to a standard feature may be used to identify information about the drug reservoir 1000, 1002.
  • system 100 may be further configured to detect the position of the coded material 120.
  • system 100 may be configured to detect the position of the coded material 120 relative to the axial length from the distal end 1004 of a drug reservoir. 1000
  • coded material 120 at position 1010 may indicate to system 100 that the drug reservoir is reservoir 1000.
  • Coded material 120 at position 1020 may indicate to system 100 that the drug reservoir is a reservoir 1006.
  • Coded material 120 at position 1030 may indicate to system 100 that the drug reservoir is a reservoir 1008. If position is used for the coding, the position on different drug reservoirs 1000, 1002, 1006, 1008 is preferably far enough apart (e.g. 10 millimeters (mm)) so that the drugs may be accurately distinguished from one another.
  • mm millimeters
  • the coded material 120 may be aligned with the connector(s) 104, 104a-c of system 100 when a drug reservoir is loaded. Alignment may be accomplished in various manners, such as aligning the coded material 120 with the connector 104 of system 100 using a mechanical protrusion or indentation in the drug reservoir to force alignment. Alignment may be of particular benefit when the arrangement of the connectors 104a-c of the detector feature 100 is important when connected to the coded material 120. However, in other situations, alignment may not be necessary, such as in the case where the connector 104 is a contactless connector.
  • the multiple areas of coding may be read during insertion into the reading apparatus, so that only one connector 104 is needed.
  • a reservoir may have three areas of coding material 120, such as a coded area indicating a storage condition, a coded area indicating the type of drug, and a coded area indicating expiration date. These coded areas may be displaced vertically 5mm apart from one another. As a drug reservoir is inserted into the system 100, the system 100 may communicate with the coded areas at each 5mm interval and may identify electrical property or properties of all three coded materials 120.
  • the present disclosure results in a number of advantages. For example, the present disclosure results in a user-friendly system that identifies information related to a drug reservoir automatically by electronic means.
  • a user-friendly system that identifies information related to a drug reservoir automatically by electronic means.
  • coding materials that may be used. Consequently, with the disclosed coding scheme, a large number of medicaments can be distinguished from one another.
  • the disclosed coding scheme if a user attempts to load an incorrect reservoir, the user may be alerted at an early stage of the assembly step that the user is attempting to load in incorrect reservoir and, hence, attempting to possibly use a wrong medicament.
  • the disclosed system and method may make drug reservoirs difficult to counterfeit.
  • the disclosed system and method may beneficially reduce tampering and/or counterfeiting of drug reservoirs. Because such reservoirs with coded materials may be difficult to tamper with, they may also reduce the risk of counterfeiting: i.e. making it more difficult for counterfeiters to provide unregulated counterfeit medicament carrying products.
  • an additional benefit is that no electrical contacts are needed.
  • Another benefit is that the disclosed method and system provides a low-cost coding scheme for coding drug reservoirs and providing information about drug reservoirs.
  • the present disclosure may apply to other drugs.
  • the present disclosure may apply to various devices, including the following examples; an injector pen with a cartridge (e.g. 3ml cylindrical glass cartridge) and a separate holder as illustrated in Figure 3A .
  • the present disclosure may also apply to an injector pen with a cartridge (e.g. 3ml cylindrical glass cartridge) non-removably retained in a holder, so that the holder will be disposed of with the primary pack, and to an injector pen where the primary pack attaches directly to the pen, e.g. an injection-moulded polymer cartridge.
  • coding features such as a coded material 120 may be added to a pouch, such as the pouch 1100 illustrated in Figure 11 .
  • coding features are added to port 1102.
  • coded material 120 may also be added to the body 1104 of the pouch 1100.
  • FIG. 12 Another example of a device that may include system 100 is shown in Figure 12 .
  • a drug delivery device 1200 which is a credit-card-shaped drug delivery device.
  • Drug delivery device 1200 comprises a body 1202.
  • Body 1202 includes a cartridge retaining portion 1204 into which a cartridge 1206 may be inserted.
  • system 100 may detect information related to the coded material 120 of the cartridge.
  • Device 1200 also includes a screen 1208, which may display information related to the cartridge 1206 to the user of the device 1200. It should be understood that system 100 may be used in various other devices as well.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Business, Economics & Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Business, Economics & Management (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Claims (7)

  1. Medizinische Verabreichungsvorrichtung (300, 1200), die Folgendes umfasst:
    - eine Medikamentenbehälterhalterung (304, 1204), die dazu ausgebildet ist, einen Medikamentenbehälter (320, 1000, 1002, 1006, 1008) aufzunehmen;
    - einen Detektor (100, 500, 600, 700, 904) zum Detektieren von Informationen in Bezug auf den Medikamentenbehälter (320, 1000, 1002, 1006, 1008), wobei der Detektor (100, 500, 600, 700, 904) so ausgestaltet ist, dass er dazu funktionsfähig ist, eine elektrische Eigenschaft in Bezug auf ein codiertes Material (120, 502, 606, 708, 900) zu bestimmen, das auf dem Medikamentenbehälter (320, 1000, 1002, 1006, 1008) angeordnet ist, wobei das codierte Material (120, 502, 606, 708, 900) zumindest einen Schaltkreis (122, 400, 800, 802, 804a-e, 902, 906, 908) umfasst, und basierend zumindest auf der bestimmten elektrischen Eigenschaft Informationen in Bezug auf den Medikamentenbehälter (320, 1000, 1002, 1006, 1008) zu bestimmen,
    wobei der Detektor (100, 500, 600, 700, 904) einen Prozessor (102) und einen Datenspeicher (108), der durch den Prozessor (102) ausführbare Anweisungen (110) umfasst, umfasst, wobei, wenn ein Benutzer versucht, den Medikamentenbehälter (320, 1000, 1002, 1006, 1008) in die medizinische Verabreichungsvorrichtung (300, 1200) zu laden, die Anweisungen (110) ferner durch den Prozessor (102) ausführbar sind, um Folgendes basierend auf den bestimmten Informationen durchzuführen:
    - Identifizieren des Medikamentenbehälters (320, 1000, 1002, 1006, 1008), Bestimmen, ob der Medikamentenbehälter (320, 1000, 1002, 1006, 1008) zur Verwendung mit der medizinischen Verabreichungsvorrichtung (300, 1200) vorgesehen ist, dadurch gekennzeichnet, dass die Anweisungen ferner durch den Prozessor (102) ausführbar sind zum
    - Steuern einer Dosisauswahl basierend auf dem identifizierten Medikamentenbehälter (320, 1000, 1002, 1006, 1008), wobei das Steuern einer Dosisauswahl Verhindern einer Dosisauswahl, wenn der identifizierte Medikamentenbehälter (320, 1000, 1002, 1006, 1008) nicht zur Verwendung mit der medizinischen Verabreichungsvorrichtung (300, 1200) vorgesehen ist, und Einstellen einer maximalen Dosis oder Einstellen einer minimalen Dosis, wenn der identifizierte Medikamentenbehälter (320, 1000, 1002, 1006, 1008) zur Verwendung mit der medizinischen Verabreichungsvorrichtung (300, 1200) vorgesehen ist, umfasst, und zum
    - Steuern einer Abgabe des Medikaments (322) basierend auf dem identifizierten Medikamentenbehälter (320, 1000, 1002, 1006, 1008), wobei das Steuern einer Abgabe des Medikaments (322) basierend auf dem identifizierten Medikamentenbehälter (320, 1000, 1002, 1006, 1008) Verhindern einer Abgabe des Medikaments (322), wenn der identifizierte Medikamentenbehälter (320, 1000, 1002, 1006, 1008) nicht zur Verwendung mit der medizinischen Verabreichungsvorrichtung (300, 1200) vorgesehen ist, und Steuern einer Abgabegeschwindigkeit und einer notwendigen Abgabekraft, wenn der identifizierte Medikamentenbehälter (320, 1000, 1002, 1006, 1008) zur Verwendung mit der medizinischen Verabreichungsvorrichtung (300, 1200) vorgesehen ist, umfasst.
  2. Medizinische Verabreichungsvorrichtung (300, 1200) nach Anspruch 1, die ferner Folgendes umfasst:
    eine Anzeige (114), die dazu ausgestaltet ist, zumindest einen Teil der Informationen in Bezug auf den Medikamentenbehälter (320, 1000, 1002, 1006, 1008) anzuzeigen.
  3. Medizinische Verabreichungsvorrichtung (300, 1200) nach Anspruch 1 oder 2,
    wobei zumindest eine Komponente des zumindest einen Schaltkreises (122, 400, 800, 802, 804a-e, 902, 906, 908) auf den Medikamentenbehälter (320, 1000, 1002, 1006, 1008) gedruckt ist.
  4. Medizinische Verabreichungsvorrichtung (300, 1200) nach Anspruch 3,
    wobei der Detektor (100, 500, 600, 700, 904) einen Oszillator umfasst und wobei die bestimmte elektrische Eigenschaft eine Resonanzfrequenz des zumindest einen Schaltkreises (122, 400, 800, 802, 804a-e, 902, 906, 908) und/oder eine Abschwächung des zumindest einen Schaltkreises (122, 400, 800, 802, 804a-e, 902, 906, 908) umfasst.
  5. Medizinische Verabreichungsvorrichtung (300, 1200) nach Anspruch 3,
    wobei der zumindest eine Schaltkreis (122, 400, 800, 802, 804a-e, 902, 906, 908) einen Tiefpassfilter oder einen Hochpassfilter umfasst und wobei die bestimmte elektrische Eigenschaft eine durchgelassene und/oder gesperrte Frequenz umfasst.
  6. Medizinische Verabreichungsvorrichtung (300, 1200) nach einem der Ansprüche 1 bis 5,
    wobei der Detektor (100, 500, 600, 700, 904) einen elektrischen Verbinder (1, 2, 3, 4, 5, 104, 104a-c, 702) zum Kommunizieren mit dem codierten Material (120, 502, 606, 708, 900) umfasst und wobei der elektrische Verbinder (1, 2, 3, 4, 5, 104, 104a-c, 702) ein kontaktaufweisender oder kontaktloser elektrischer Verbinder (1, 2, 3, 4, 5, 104, 104a-c, 702) ist.
  7. Medizinische Verabreichungsvorrichtung (300, 1200) nach einem der Ansprüche 1 bis 5,
    wobei die Anweisungen (110) ferner durch den Prozessor (102) ausführbar sind, um Folgendes durchzuführen:
    - Anzeigen einer Angabe, dass der Medikamentenbehälter (320, 1000, 1002, 1006, 1008) nicht zur Verwendung mit der medizinischen Verabreichungsvorrichtung (300, 1200) vorgesehen ist, und/oder
    - Verhindern eines Einsetzens des Medikamentenbehälters (320, 1000, 1002, 1006, 1008) in die medizinische Verabreichungsvorrichtung (300, 1200).
EP11752511.3A 2010-08-26 2011-08-25 Verfahren und system zur bestimmung von informationen im zusammenhang mit einem arzneimittelreservoir Active EP2608827B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11752511.3A EP2608827B1 (de) 2010-08-26 2011-08-25 Verfahren und system zur bestimmung von informationen im zusammenhang mit einem arzneimittelreservoir

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37712810P 2010-08-26 2010-08-26
EP10188858 2010-10-26
EP11752511.3A EP2608827B1 (de) 2010-08-26 2011-08-25 Verfahren und system zur bestimmung von informationen im zusammenhang mit einem arzneimittelreservoir
PCT/EP2011/064629 WO2012025590A2 (en) 2010-08-26 2011-08-25 Method and system for determining information related to a drug reservoir

Publications (2)

Publication Number Publication Date
EP2608827A2 EP2608827A2 (de) 2013-07-03
EP2608827B1 true EP2608827B1 (de) 2019-05-01

Family

ID=43648715

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11752511.3A Active EP2608827B1 (de) 2010-08-26 2011-08-25 Verfahren und system zur bestimmung von informationen im zusammenhang mit einem arzneimittelreservoir

Country Status (4)

Country Link
US (1) US9814846B2 (de)
EP (1) EP2608827B1 (de)
JP (1) JP6104159B2 (de)
WO (1) WO2012025590A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8579866B2 (en) 2008-01-11 2013-11-12 Ucb Pharma, S.A. Systems and methods for administering medication
WO2012164403A2 (en) 2011-06-02 2012-12-06 Ucb Pharma S.A. Auto-injector
WO2014019997A1 (en) 2012-07-30 2014-02-06 Ucb Pharma S.A. Auto-injector
WO2014020000A1 (en) 2012-07-30 2014-02-06 Ucb Pharma S.A. Auto-injector
US9757524B2 (en) 2012-07-30 2017-09-12 Ucb Biopharma Sprl Auto-injector
US9757513B2 (en) 2012-07-30 2017-09-12 Ucb Biopharma Sprl Auto-injector
FI124914B (fi) * 2012-09-21 2015-03-31 Stora Enso Oyj Monipuolinen ja luotettava älypakkaus
US10342925B2 (en) 2014-01-27 2019-07-09 Ucb Biopharma Sprl Auto-injector
EP3099352B1 (de) 2014-01-27 2019-03-13 UCB Biopharma SPRL Automatischer injektor
US10564129B2 (en) * 2014-08-08 2020-02-18 Sanofi-Aventis Deutschland Gmbh Method and arrangement for acoustically testing the mechanical integrity of a cartridge
US10971260B2 (en) 2014-09-14 2021-04-06 Becton, Dickinson And Company System and method for capturing dose information
US10704944B2 (en) 2014-09-14 2020-07-07 Becton, Dickinson And Company System and method for capturing dose information

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US533575A (en) 1895-02-05 wilkens
US5226895A (en) 1989-06-05 1993-07-13 Eli Lilly And Company Multiple dose injection pen
GB9007113D0 (en) 1990-03-29 1990-05-30 Sams Bernard Dispensing device
EP0525525B1 (de) 1991-07-24 1995-05-03 Medico Development Investment Company Injektor
DK175491D0 (da) 1991-10-18 1991-10-18 Novo Nordisk As Apparat
US5279585A (en) 1992-02-04 1994-01-18 Becton, Dickinson And Company Medication delivery pen having improved dose delivery features
SE9201247D0 (sv) * 1992-04-21 1992-04-21 Kabi Pharmacia Ab Injection device
US5320609A (en) 1992-12-07 1994-06-14 Habley Medical Technology Corporation Automatic pharmaceutical dispensing syringe
US5383865A (en) 1993-03-15 1995-01-24 Eli Lilly And Company Medication dispensing device
ZA941881B (en) 1993-04-02 1995-09-18 Lilly Co Eli Manifold medication injection apparatus and method
US5582598A (en) 1994-09-19 1996-12-10 Becton Dickinson And Company Medication delivery pen with variable increment dose scale
NZ302558A (en) 1995-03-07 1999-11-29 Lilly Co Eli Dispensing apparatus with a medication cartridge with a manually adjustable metering mechanism
US5688251A (en) 1995-09-19 1997-11-18 Becton Dickinson And Company Cartridge loading and priming mechanism for a pen injector
US5674204A (en) 1995-09-19 1997-10-07 Becton Dickinson And Company Medication delivery pen cap actuated dose delivery clutch
DK0921827T3 (da) * 1996-07-01 2003-12-22 Pharmacia Ab Afgiveanordning og fremgangsmåde til drift af samme
DE19730999C1 (de) 1997-07-18 1998-12-10 Disetronic Licensing Ag Dosierknopfsicherung an einer Vorrichtung zur dosierten Verabreichung eines injizierbaren Produkts
US5921966A (en) 1997-08-11 1999-07-13 Becton Dickinson And Company Medication delivery pen having an improved clutch assembly
US6004297A (en) 1998-01-30 1999-12-21 Novo Nordisk A/S Injection syringe
US6221053B1 (en) 1998-02-20 2001-04-24 Becton, Dickinson And Company Multi-featured medication delivery pen
US5961495A (en) 1998-02-20 1999-10-05 Becton, Dickinson And Company Medication delivery pen having a priming mechanism
US6248095B1 (en) 1998-02-23 2001-06-19 Becton, Dickinson And Company Low-cost medication delivery pen
JP2002518108A (ja) * 1998-06-15 2002-06-25 メドラッド インコーポレイテッド シリンジ情報のコード化
AU6892100A (en) 1999-08-05 2001-03-05 Becton Dickinson & Company Medication delivery pen
AU2001223397A1 (en) * 2000-02-01 2001-08-14 Disetronic Licensing Ag Configurable device and method for releasing a substance
WO2001056635A1 (de) 2000-02-01 2001-08-09 Disetronic Licensing Ag Behälter und vorrichtung zur verabreichung einer substanz
GB0003197D0 (en) * 2000-02-11 2000-04-05 Aid Medic Ltd Improvements in and relating to controlling drug delivery
GB0007071D0 (en) 2000-03-24 2000-05-17 Sams Bernard One-way clutch mechanisms and injector devices
US6663602B2 (en) 2000-06-16 2003-12-16 Novo Nordisk A/S Injection device
US6899699B2 (en) 2001-01-05 2005-05-31 Novo Nordisk A/S Automatic injection device with reset feature
EP1392377B1 (de) 2001-05-16 2007-02-28 Eli Lilly And Company Arzneimitteleinspritzvorrichtung mit rückstellung erleichternder antriebsanordnung
US20030055685A1 (en) * 2001-09-19 2003-03-20 Safety Syringes, Inc. Systems and methods for monitoring administration of medical products
GB0304823D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
HUE026224T2 (en) * 2004-02-18 2016-06-28 Ares Trading Sa Portable, electronically controlled injection device for injecting liquid drugs
DE102004063644A1 (de) 2004-12-31 2006-07-20 Tecpharma Licensing Ag Vorrichtung zur dosierten Verabreichung eines fluiden Produkts mit Drehfederantrieb
CA2625359A1 (en) * 2005-10-11 2007-04-19 Blake Podaima Smart medical compliance method and system
US7871399B2 (en) * 2006-05-17 2011-01-18 Alcon Research, Ltd. Disposable ophthalmic injection device
CN101681421A (zh) 2007-06-09 2010-03-24 诺沃-诺迪斯克有限公司 贮存器识别码的无接触读取
US8647309B2 (en) 2008-05-02 2014-02-11 Sanofi-Aventis Deutschland Gmbh Medication delivery device
WO2010092156A1 (en) * 2009-02-13 2010-08-19 Novo Nordisk A/S Medical device and cartridge

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
WO2012025590A3 (en) 2012-11-15
WO2012025590A2 (en) 2012-03-01
JP6104159B2 (ja) 2017-03-29
US20130226139A1 (en) 2013-08-29
JP2013536031A (ja) 2013-09-19
US9814846B2 (en) 2017-11-14
EP2608827A2 (de) 2013-07-03

Similar Documents

Publication Publication Date Title
EP2608827B1 (de) Verfahren und system zur bestimmung von informationen im zusammenhang mit einem arzneimittelreservoir
EP2605815B1 (de) Verfahren und system zur bestimmung von informationen in bezug auf ein arzneimittelreservoir mithilfe eines elektronischen sensors
EP2560706B1 (de) Patronenhalter und ausrichtungsschnittstelle
US8784378B2 (en) Drug delivery device with light source
EP2555818A2 (de) Codierte verschlusskappe zur verwendung mit einer arzneimittelverabreichungsvorrichtung
WO2011131779A1 (en) Drug delivery device and drug reservoir with mechanical coding mechanism
EP2603258B1 (de) Mechanismus zum verhindern der auswahl einer dosierung
US20140128842A1 (en) Medicament Administration
EP2648785B1 (de) Originalitätsanzeige für ein arzneimittelreservoir
WO2012010564A1 (en) Medicament cartridges with non-standard dimensions
EP2621562A1 (de) Nicht abnehmbarer reservoirhalter für eine arzneimittelabgabevorrichtung
US20170128325A1 (en) Reminder device
EP2603259B1 (de) Codiersystem für eine wirkstofffreisetzungsvorrichtung und wirkstofffreisetzungssystem

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130515

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20150204

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602011058521

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61M0005240000

Ipc: A61M0005500000

RIC1 Information provided on ipc code assigned before grant

Ipc: A61M 5/50 20060101AFI20180820BHEP

Ipc: G06F 19/00 20110101ALI20180820BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20181116

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1126105

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190515

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011058521

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20190724

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20190501

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190901

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190801

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190801

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190802

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1126105

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011058521

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20200204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190825

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20190831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190825

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20110825

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230823

Year of fee payment: 13

Ref country code: CH

Payment date: 20230902

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240702

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20240813

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240701

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240702

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240901

Year of fee payment: 14